Potential role of endotoxin as a proinflammatory mediator of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 12, 2004, Pages 2227-2236

  Stoll, Lynn L ^a   Denning, Gerene M ^a   Weintraub, Neal L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Endothelial cells; Inflammation; Lipopolysaccharide; Species specificity; Vascular smooth muscle cells

Indexed keywords

ARACHIDONIC ACID; BETA2 INTEGRIN; C REACTIVE PROTEIN; CD14 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; ENDOTOXIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; STATIN; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BACTERIAL MUTATION; CARDIOVASCULAR DISEASE; CAUCASIAN; CHLAMYDOPHILA PNEUMONIAE; ENDOTOXEMIA; GENETIC POLYMORPHISM; GRAM NEGATIVE INFECTION; HUMAN; INFLAMMATORY DISEASE; LIPOPROTEIN BLOOD LEVEL; MEDIATOR; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ARTERIOSCLEROSIS; ENDOTOXINS; HUMANS; INFLAMMATION;

EID: 10644230298     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000147534.69062.dc     Document Type: Short Survey

References (175)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
2. de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis, inflammation, and infection. J Pathol 2000;190:237-243.
3. Gerszten RE, Mach F, Saury A, Rosenzweig A, Luster AD. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med. 2000;136:87-92.
4. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516.
5. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
6. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
7. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291.
8. Curtiss LK, Kubo N, Schiller NK, Boisvert WA. Participation of innate and acquired immunity in atherosclerosis. Immunol Res. 2000;21:167-176.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
10. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy Am women. Circulation. 2003;107:391-397.
11. Rietschel ET, Kirikae T, Schade FU, Mamet U, Schmidt G, Loppnow H, Ulmer AJ, Zahringer U, Seydel U, Di Padova F, Schreier M, Brade H. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 1994;8:217-225.
12. Preston A, Mandrell RE, Gibson BW, Apicella MA. The lipooligosaccharides of pathogenic Gram-negative bacteria. Crit Rev Microbiol. 1996;22:139-180.
13. Wilkinson SG. Bacterial lipopolysaccharides-themes and variations. Prog Lipid Res. 1996;35:283-343.
14. Holst O, Ulmer AJ, Brade H, Flad H-D, Rietschel ET. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol. 1996;16:83-104.
15. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002;71:635-700.
16. Li L, Messas E, Batista EL, Jr., Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation. 2002;105:861-867.
17. De Nardin E. The role of inflammatory and immunological mediators in periodontitis and cardiovascular disease. Annals of Periodontology. 2001;6:30-40.
18. Kuramitsu HK, Kang IC, Qi M. Interaction of Porphyromonas gingivalis with host cells: implications for cardiovascular diseases. J Periodontology. 2003;74:85-89.
19. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease. Prospective results from the Bruneck study. J Am Coll Cardiol. 1999;34:1975-1981.
20. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001;103:1064-1070.
21. Schratzberger P, Kiechl S, Dunzendorfer S, Kahler CM, Patsch JR, Willeit J, Wiedermann CJ. Plasma-induced endothelial activation associated with incident atherosclerosis: prospective results from the Bruneck Study. J Cardiovasc Risk. 2000;7:285-291.
22. Lehr H-A, Sagban TA, Ihling C, Zanringer U, Hungerer K-D, Blumrich M, Reifenberg K, Bhakdi S. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation. 2001;104:914-920.
23. Ostos MA, Recalde D, Zakin MM, Scott-Algara D. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett. 2002;519:23-29.
24. Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis. 1986;133:913-927.
25. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sorensen E. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis. 1989;159:195-204.
26. Levi M, ten Cate JW, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA. 1993;25:975-979.
27. Bannerman DD, Goldblum SE. Direct effects of endotoxin on the endothelium: barrier function and injury. Lab Invest. 1999;79:1181-1199.
28. Rice JB, Stoll LL, Li W-G, Denning GM, Weydert J, Charipar E, Richenbacher WE, Miller FJ, Jr, Weintraub NL. Low level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arteriosclerosis, Thrombosis and Vascular Biology. 2003;23:1576-1582.
29. Stoll LL, Denning GM, Li WG, Rice JB, Harrelson AL, Romig SA, Gunnlaugsson ST, Miller FJ, Jr, Weintraub NL. Regulation of endotoxin-induced proinflammatory activation in human coronary artery cells: expression of functional membrane-bound CD14 by human coronary artery smooth muscle cells. J Immunol. 2004;173:1336-1343.
30. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem. 1996;271:4100-4105.
31. Fenton MJ, Golenbock D. LPS-binding proteins and receptors. J Leukocyte Biol. 1998;64:25-32.
32. Read TE, Harris HW, Grunfeld C, Feingold KR, Kane JP, Rapp JH. The protective effect of serum lipoproteins against bacterial lipopolysaccharide. Eur Heart J. 1993;14(Suppl. K):125-129.
33. Van Bossuyt H, De Zanger RB, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol. 1988;7:325-337.
34. Flegel WA, Wölpl A, Männel D, Northoff H. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun. 1989;57:2237-2245.
35. Feingold KR, Funk JL, Moser AH, Shigenaga JK, Rapp JH, Grunfeld C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun. 1995;63:2041-2046.
36. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:12040-12044.
37. Parker TS, Levine DM, Chang JCC, Laxer J, Coffin CC, Rubin AL. Reconstituted high-density lipoprotein neutralizes Gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun. 1995;63:253-258.
38. Antal-Szalmas P. Evaluation of CD14 in host defense. Eur J Clin Invest. 2000;30:167-179.
39. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M, Glauser MP, Tobias PS, Ulevitch RJ. CD14 is a pattern recognition receptor. Immunity. 1994;1:509-516.
40. Viriyakosol S, Kirkland TN. The N-terminal half of membrane CD14 is a functional cellular lipopolysaccharide receptor. Infection and Immunity. 1996;64:653-656.
41. Golenbock DT, Liu Y, Millham FH, Freeman MW, Zoeller RA. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin. J Biol Chem. 1993;268:22055-22059.
42. Unkelbach K, Gardemann A, Kostrzewa M, Philipp M, Tillmanns H, Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol. 1999;19:932-938.
43. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, Drouet L, Ferrieres J. Soluble CD14 and aortic stiffness in a population-based study. J Hypertens. 2003;21:1869-1877.
44. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176:1665-1671.
45. Tapping RI, Tobias PS. Soluble CD14-mediated cellular responses to lipopolysaccharide. Chem Immunol. 2000;74:108-121.
46. Jersmann HPA, Hii CST, Hodge GL, Ferrante A. Synthesis and surface expression of CD14 by human endothelial cells. Infection and Immunity. 2001;69:479-485.
47. Bazil V, Baudys M, Hilgert I, Stefanova I, Low MG, Zbrozek J, Horejsi V. Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol. 1989;26:657-662.
48. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci U S A. 1993;90:2744-2748.
49. Froon AHM, Dentener MA, Greve JWM, Ramsay G, Buurman WA. Lipolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995;171:1250-1257.
50. Hayashi J, Masaka T, Ishikawa I. Increased levels of soluble CD14 in sera of periodontitis patients. Infect Immun. 1999;67:417-420.
51. Landmann R, Zimmerli W, Sansano S, Link S, Hahn A, Glauser MP, Calandra T. Increased circulating soluble CD14 is associated with high mortality in gram-negative shock. J Infect Dis. 1995;171:639-644.
52. Lamping N, Dettmer R, Schröder NWJ, Pfeil D, Hallatschek W, Burger R. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest. 1998;101:2065-2071.
53. Means TK, Golenbock DT, Fenton MJ. Structure and function of Toll-like receptor proteins. Life Sci. 2000;68:241-258.
54. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274:10689-10692.
55. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999;189:1777-1782.
56. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem. 2001;276:38044-38051.
57. Nagai Y, Akasni S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002;3:667-672.
58. Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, Weiss JP. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci U S A. 2004;101:4186-4191.
59. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000;275:11058-11063.
60. Xu XH, Shah P, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu X-P, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation. 2001;104:3103-3108.
61. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation. 2002;105:1158-1161.
62. Schwartz DA. The role of TLR4 in endotoxin responsiveness in humans. J Endotoxin Res. 2001;7:389-393.
63. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genetics. 2000;25:187-191.
64. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185-192.
65. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, Lamotte M, Lebret D, Ollivier V, de Prost D. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol. 2003;23:e61-e64.
66. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis. 2003;170:187-190.
67. Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, de Boo T, Van der Meer JW, Kastelein JJ, Stalenhorf AF. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest. 2004;34:94-99.
68. Oyama J, Blais C, Jr., Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004;109:784-789.
69. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, Patel S, Card DJ, Hermanowski-Vosatka A, Bergstrom JD, Sparrow CP, Detmers PA, Chao YS. Infectious agents are not necessary for murine atherogenesis. J Exp Med. 2000;191:1437-1442.
70. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest. 2004;34:328-334.
71. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol. 2003;23:15-44.
72. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276:16683-16689.
73. Hwang D. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4-derived signaling pathways. Faseb J. 2001;15:2556-2564.
74. Gangloff SC, Hijiya N, Haziot A, Goyert SM. Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Clin Infect Dis. 1999;28:491-496.
75. Ingalls RR, Golenbock DT. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med. 1995;181:1473-1479.
76. Peppelenbosch MP, DeSmedt M, ten Hove T, van Deventer SJ, Grooten J. Lipopolysaccharide regulates macrophage fluid phase pinocytosis via CD14-dependent and CD14-independent pathways. Blood. 1999;93:4011-4018.
77. Triantafilou K, Triantafilou M, Dedrick RL. A CD14-independent LPS receptor cluster. Nat Immunol. 2001;2:338-345.
78. Perera PY, Vogel SN, Detore GR, Haziot A, Goyert SM. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol. 1997;158:4422-4429.
79. Bartels C, Maass M, Bein G, Malisius R, Brill N, Bechtel JF, Sayk F, Feller AC, Sievers HH. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation. 1999;99:879-882.
80. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501-1504.
81. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun. 1996;64:1614-1620.
82. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation. 1999;100:1369-1373.
83. Fong I. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. Can Med Assoc J. 2000;163:49-56.
84. Shor A, Phillips JI. Chlamydia pneumoniae and atherosclerosis. JAMA. 1999;282:2071-2073.
85. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2724-2731.
86. Kosma P. Chlamydial lipopolysaccharide. Biochim Biophys Acta. 1999;1455:387-402.
87. Heine H, Muller-Loennies S, Brade L, Lindner B, Brade H. Endotoxic activity and chemical structure of lipopolysaccharides from Chlamydia trachomatis serotypes E and L2 and Chlamydophila psittaci 6BC. Eur J Biochem. 2003;270:440-450.
88. Prebeck S, Brade H, Kirschning CJ, da Costa CP, Durr S, Wagner H, Miethke T. The Gram-negative bacterium Chlamydia trachomatis L2 stimulates tumor necrosis factor secretion by innate immune cells independently of its endotoxin. Microbes Infect. 2003;5:463-470.
89. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J. 1993;14(Suppl K):57-61.
90. Qureshi N, Kaltashov I, Walker K, Doroshenko V, Cotter RJ, Takayama K, Sievert TR, Rice PA, Lin JS, Golenbock DT. Structure of the monophosphoryl lipid A moiety obtained from the lipopolysaccharide of Chlamydia trachomatis. J Biol Chem. 1997;272:10594-10600.
91. Zahringer U, Lindner B, Knirel YA, van den Akker WM, Hiestand R, Heine H, Dehio C. Structure and biological activity of the short-chain lipopolysaccharide from Bartonella henselae ATCC 49882T. J Biol Chem. 2004;279:21046-21054.
92. Rund S, Lindner B, Brade H, Holst O. Structural analysis of the lipopolysaccharide from Chlamydia trachomatis serotype L2. J Biol Chem. 1999;274:16819-16824.
93. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun. 1995;63:3125-3130.
94. Netea MG, Kullberg BJ, Galama JM, Stalenhoef AF, Dinarello CA, Van der Meer JW. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol. 2002;32:1188-1195.
95. Netea MG, Selzman CH, Kullberg BJ, Galama JM, Weinberg A, Stalenhoef AF, Van der Meer JW, Dinarello CA. Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 2000;30:541-549.
96. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, Morrison SG, Morrison RP, Arditi M. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol. 2002;168:1435-1440.
97. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol. 2000;164:13-17.
98. Christiansen G, Boesen T, Hjerno K, Daugaard L, Mygind P, Madsen AS, Knudsen K, Falk E, Birkelund S. Molecular biology of Chlamydia pneumoniae surface proteins and their role in immunopathogenicity. Am Heart J. 1999;138:S491-S495.
99. Flegel WA, Baumstark MW, Weinstock C, Berg A, Normoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infection and Immunity. 1993;61:5140-5146.
100. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJH. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 1996; 184:1601-1608.
101. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H Oxidase. Role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
102. Gibbs LS, Del Vecchio PJ, Shaffer JB. Mn and Cu/Zn SOD expression in cells from LPS-sensitive and LPS-resistant mice. Free Radical Biol & Med. 1992;12:107-111.
103. Suzuki K, Tatsumi H, Satoh S, Senda T, Nakata T, Jujii J, Tanaguchi N. Manganese-superoxide dismutase in endothelial cells: localization and mechanism of induction. Am J Physiol. 1993;265:H1173-H1178.
104. Kong X-J, Fanburg BL. Regulation of Cu,Zn-superoxide dismutase in bovine pulmonary artery endothelial cells. J Cell Physiol. 1992;153:491-497.
105. Ulevitch RJ, Tobias PS. Receptor-dependent mechanism of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995;13:437-457.
106. DeLeo FR, Renee J, McCormick S, Nakamura M, Apicella MA, Weiss JP, Nauseef WM. Neutrophils exposed to bacterial lipopolysaccharide up-regulate NADPH oxidase assembly. J Clin Invest. 1998;101:5911-5917.
107. phox-based NADH oxidase in vascular smooth muscle. Biochem J. 1998;329:653-657.
108. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
109. phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem. 1999;274:19814-19822.
110. +. Circ Res. 1998;83:730-737.
111. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte cheomattractant protein-1 in human aortic smooth muscle cells. Circulation. 1997;96:2361-2367.
112. Li WG, Miller FJ, Jr., Zhang HJ, Spitz DR, Oberley LW, Weintraub NL. H(2)O(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem. 2001;276:29251-29256.
113. Brandes RP, Koddenberg G, Gwinner W, Kim D, Kruse HJ, Busse R, Mugge A. Role of increased production of superoxide anions by NAD(P)H oxidase and xanthine oxidase in prolonged endotoxemia. Hypertension. 1999;33:1243-1249.
114. Reape TJ, Groot PHE. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213-225.
115. Ben-Baruch A, Michiel DF, Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem. 1995;270:11703-11706.
116. Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today. 1989;10:370-375.
117. Elias JA, Zitnik RJ. Cytokine-cytokine interactions in the context of cytokine networking. Am J Respir Cell Mol Biol. 1992;7:365-367.
118. Hajjar DP, Pomerantz KB. Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. Faseb J. 1992;6:2933-2941.
119. Taga T, Kishimoto T. Cytokine receptors and signal transduction. FASEB J. 1992;6:3387-3396.
120. Calandra T. Macrophage migration inhibitory factor and host innate immune responses to microbes. Scand J Infect Dis. 2003;35:573-576.
121. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999;189:341-346.
122. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol. 1996;60:8-26.
123. Diks SH, van Deventer SJH, Peppelenbosch MP. Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. J Endotoxin Res. 2001;7:335-348.
124. Strieter RM, Remick DG, Ham JM, Colletti LM, Lynch JP, 3rd, Kunkel SL. Tumor necrosis factor-α gene expression in human whole blood. J Leukoc Biol. 1990;47:366-370.
125. Dickensheets HL, Freeman SL, Smith MF, Donnelly RP. Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes. Blood. 1997;90:4162-4171.
126. Harrington JR. The role of MCP-1 in atherosclerosis. Stem Cells. 2000;18:65-66.
127. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-281.
128. Aiello RJ, Bourassa P-A, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:1518-1525.
129. 2 activation in human neutrophils. Immunology. 1992;75:157-163.
130. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science. 1989;243:1464-1466.
131. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Jr, Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718-723.
132. Boekholdt SM, Peters RJ, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2004;24:1503-1508.
133. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998;101:353-363.
134. Shen Y, Sultana C, Arditi M, Kim KS, Kalra VK. Endotoxin-induced migration of monocytes and PECAM-1 phosphorylation are abrogated by PAF receptor antagonists. Am J Physiol. 1998;275:E479-E486.
135. Brown EJ. Adhesive interactions in the immune system. Trends in Cell Biology. 1997;7:289-295.
136. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. Faseb J. 1994;8:504-512.
137. Newman PJ. The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci. 1994;714:165-174.
138. Pohlman TH, Stanness KA, Beatty PG, Ochs HD, Harlan JM. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-α increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol. 1986;136:4548-4553.
139. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995;9:866-873.
140. Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Lou D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Int Med. 1999;159:1793-1802.
141. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med. 2000;32:164-176.
142. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol. 2001;21:3-5.
143. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang P-R, Zhang D, Peterson L, Detmers PA, Chao Y-S, Wright SD. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115-121.
144. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Salmona M. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001;21:1327-1332.
145. Inoue I, Goto S-i, Mizotani K, Awata T, Mastunaga T, Kawai S-i, Nakajima T, Hokari S, Komoda T, Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect. Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci. 2000;67:863-876.
146. Pahan K, Sheikh FG, Namboodiri AMS, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997; 100:2671-2679.
147. Takeuchi S, Kawashima S, Rikitake Y, Ueyama T, Inoue N, Hirata K, Yokoyama M. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun. 2000;269:97-102.
148. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther. 2000;294:1043-1046.
149. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation. 2004;109:2560-2565.
150. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis. 2001;33:1352-1357.
151. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest. 2003;124:740-743.
152. Casey PJ. Protein lipidation in cell signaling. Science. 1995;268:221-225.
153. Wagner AH, Köhler T, Rückscloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
154. Rubio I, Wittig U, Meyer C, Heinze R, Kadereit D, Waldmann H, Downward J, Wetzker R. Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase γ. Eur J Biochem. 1999;266: 70-82.
155. Wheeler MD, Thurman RG. Up-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP-1 pathway. J Biol Chem. 2003;278:8435-8441.
156. Saluk-Juszczak J, Wachowicz B, Kaca W. Endotoxins stimulate generation of superoxide radicals and lipid peroxidation in blood platelets. Microbios. 2000;103:17-25.
157. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Anti-oxidant effects of statins. Drugs Today. 2004;(in press).
158. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869-871.
159. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med. 1982;3:35-56.
160. Jungi TW, Adler H, Adler B, Thony M, Krampe M, Peterhans E. Inducible nitric oxide synthase of macrophages. Present knowledge and evidence for species-specific regulation. Vet Immunol Immunopathol. 1996;54:323-330.
161. Dirami G, Massaro D, Clerch LB. Regulation of lung manganese superoxide dismutase: species variation in response to lipopolysaccharide. Am J Physiol. 1999;276:L705-L708.
162. Dorger M, Jesch NK, Rieder G, Hirvonen MR, Savolainen K, Krombach F, Messmer K. Species differences in NO formation by rat and hamster alveolar macrophages in vitro. Am J Respir Cell Mol Biol. 1997;16:413-420.
163. Heyes MP, Saito K, Chen CY, Proescholdt MG, Nowak TS, Jr., Li J, Beagles KE, Proescholdt MA, Zito MA, Kawai K, Markey SP. Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation. J Neurochem. 1997;69:1519-1529.
164. Redl H, Bahrami S, Schlag G, Traber DL. Clinical detection of LPS and animal models of endotoxemia. Immunobiology. 1993;187:330-345.
165. Gerritsen ME. Functional heterogeneity of vascular endothelial cells. Biochem Pharmacol. 1987;36:2701-2711.
166. Gumkowski F, Kaminska G, Kaminski M, Morrissey LW, Auerbach R. Heterogeneity of mouse vascular endothelium. In vitro studies of lymphatic, large blood vessel and microvascular endothelial cells. Blood Vessels. 1987;24:11-23.
167. Meyrick B, Berry LC, Jr, Christman BW. Response of cultured human pulmonary artery endothelial cells to endotoxin. Am J Physiol. 1995;268:L239-244.
168. Harlan JM, Harker LA, Reidy MA, Gajdusek CM, Schwartz SM, Striker GE. Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest. 1983;48:269-274.
169. Poltorak A, Riccairdi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. PNAS. 2000;97:2163-2167.
170. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. Lipid A-like
171. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol. 2002;3:354-359.
172. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000;105:497-504.
173. Akashi S, Nagai Y, Ogata H, Oikawa M, Fukase K, Kusumoto S, Kawasaki K, Nishijima M, Hayashi S, Kimoto M, Miyake K. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int Immunol. 2001;13:1595-1599.
174. Kawasaki K, Gomi K, Nishijima M. Cutting edge: Gln22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol. 2001;166:11-14.
175. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Riccairdi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in CeH/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085-2088.